A Weekly Roundup of Stories We Found Interesting – From The Profound To The Profane

DEA finalizing Schedule II status for synthetic THC drug Syndros
The U.S. Drug Enforcement Administration this week granted Schedule II status to a synthetic THC drug developed by Insys Therapeutics.  The same pharmaceutical company that last year donated to a campaign opposing marijuana legalization and last month saw its founder arrested on fraud and racketeering charges.

A Grow-Your-Own Pot Boom In Washington
From young tokers to elderly first-timers to avid gardeners, the grow-your-own scene has bloomed since it became legal in 2015 to keep up to six plants at home. Some get into the technique. Others are patients looking for cheaper alternatives to the medical dispensaries, which charge premium prices for medicinal marijuana not covered by insurance.

California Weed Entrepreneurs Will Make $5.2B In 2018 With Almost No Banks To Put It In
California cannabis entrepreneurs will earn $5.2B in revenue in 2018 as recreational use becomes legal there. The state of California will collect about one billion dollars in accompanying marijuana taxes. Still, banking and financial services are almost non-existing within the industry.

Cannabis on the Blockchain
Blockchain is the forefront of software technology. It has the potential to transform the cannabis industry by providing quick, encrypted financial transaction that guarantees the security of personal information.

How to Talk to Your Clueless Doctor About Smoking Weed
With the spread of medical marijuana as a treatment for mental illness, people are finding themselves in the predicament of having to speak to their mental health professionals about their medicine.

Medical Marijuana and the Science of Relief
A scientific look at how the dual-action effect of THC and CBD make marijuana a very promising new form of treatment for people suffering from some of our most serious ailments.